my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
16-04-2012: immatics biotechnologies GmbH announced the appointment of Dr. Rainer Kramer as Chief Business Officer (CBO) with immediate effect.
In this newly created role, Dr. Kramer will lead immatics’ Business Development Unit in order to create optimal value from the Company’s pipeline of therapeutic cancer vaccines.
Dr. Kramer has many years of business development experience within the pharmaceutical industry. He joins from Signature Diagnostics, an oncology diagnostics company where he was CBO. Before that, he was Vice President Business Development at Jerini AG, where he was responsible for all licensing, partnering, and alliance management activities, and played a key role in the sale of the Company to Shire in 2008. Before joining Jerini, he held various business development and research positions at MorphoSys AG, Martinsried, and Amgen Inc. Dr. Kramer holds a Diploma in Molecular Biology from the University of Regensburg and a PhD from the Max-Planck-Institute for Neurobiology.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
immatics appoints Peter Chambré as Chairman
immatics biotechnologies GmbH announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He wi ... more
Kidney Cancer Vaccine Successful in Clinical Trials
Researchers at the University of Tübingen and immatics biotechnologies GmbH – a start-up by Tübingen scientists – have published the results of two clinical studies using the kidney-cancer vaccine IMA901 in the latest edition of Nature Medicine. IMA901 is used to treat patients with cancer ... more
immatics wins 2012 TiE50 Award
immatics biotechnologies GmbH announced that it has been named a 2012 TiE50 winner. These awards recognize entrepreneurship, innovation and management excellence within the life sciences, software, internet, mobile and energy sectors. immatics was chosen from more than 2,100 technology sta ... more
immatics is developing cancer drugs that help to activate the self defense mechanisms of the human body. Our goal is to support patients and physicians with new options in the fight against various cancers. Our means are synthetic peptides that specifically activate specialized white blo ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
